Apis Insurtech Fund I, a venture fund managed by Apis Partners has led a $15 million investment in Prenetics Limited, along with existing investor Alibaba Hong Kong Entrepreneurs Fund and more.

Hong Kong headquartered Prenetics is a leading genetics and diagnostic health testing company, operational in 10 countries with a team of over 200. Prenetics, driven by a duty of responsibility due to the global pandemic launched Project Screen by Circle, an initiative aimed at making COVID-19 testing easy, safe and accurate. Highlighted below are some key updates:

• Prenetics plans to launch in Q4 a rapid COVID-19 nucleic acid test, with results in 15-30 minutes, no laboratory required, highly scalable, low-cost, enabling frequent testing. Prenetics is in talks with multiple governments globally.
• Prenetics has been selected by Pure Health, the largest laboratory network in the UAE to test airline passengers flying into the United Arab Emirates from Hong Kong, in accordance with the UAE's requirement for travelers to prove they are not infected with Covid-19. Pure Health has been appointed by the UAE's government to launch this pioneering project to promote safe travel.
• Prenetics has performed more than 300,000 RT-PCR COVID-19 tests in Hong Kong and in the U.K., having identified approximately 280 individuals as positive for COVID-19.
• Prenetics, the only Hong Kong laboratory appointed by the Hong Kong government in the 1st phase of community COVID-19 testing across high-risk clusters, which include Hospital Authority, Travellers, Restaurant Staff, Foreign Domestic Helpers, and more.
• Prenetics Hong Kong laboratory can process over 20,000 RT-PCR tests daily, making it the largest private testing laboratory in Hong Kong.
• Prenetics was selected in May 2020 by U.K. Premier League to help re-start the football season by providing 40,000 COVID-19 tests for all 20 teams. Prenetics has been chosen again for the new season as the only testing provider by the Premier League.
• Prenetics Group CEO – Danny Yeung selected by Business Insider Asia as one of 100 people transforming business in Asia. 

Alongside serving the community in the fight against COVID-19, Prenetics pioneered the use of Whole Exome Sequencing Technology with its flagship CircleDNA consumer DNA test. Via CircleDNA, individuals can, via a single saliva swab, access over 500 valuable health reports which include cancer & disease risk, carrier screening for family planning, drug response, diet & nutrition, sports, ancestry and many more.

Prenetics has now raised more than $60 million since inception in 2014. The new funding will be used to continue to invest in R&D with a specific focus on further advancing COVID-19 testing technologies on a global basis.